Your browser doesn't support javascript.
mRNA therapeutics for disease therapy: principles, delivery, and clinical translation.
Zhou, Da-Wei; Wang, Ke; Zhang, Ying-Ao; Ma, Ke; Yang, Xiao-Chun; Li, Zhen-Yi; Yu, Shou-Shan; Chen, Ke-Zheng; Qiao, Sheng-Lin.
  • Zhou DW; Lab of Functional and Biomedical Nanomaterials, College of Materials Science and Engineering, Qingdao University of Science and Technology (QUST), Qingdao, 266042, P. R. China. qiaosl@qust.edu.cn.
  • Wang K; Lab of Functional and Biomedical Nanomaterials, College of Materials Science and Engineering, Qingdao University of Science and Technology (QUST), Qingdao, 266042, P. R. China. qiaosl@qust.edu.cn.
  • Zhang YA; Lab of Functional and Biomedical Nanomaterials, College of Materials Science and Engineering, Qingdao University of Science and Technology (QUST), Qingdao, 266042, P. R. China. qiaosl@qust.edu.cn.
  • Ma K; Lab of Functional and Biomedical Nanomaterials, College of Materials Science and Engineering, Qingdao University of Science and Technology (QUST), Qingdao, 266042, P. R. China. qiaosl@qust.edu.cn.
  • Yang XC; Lab of Functional and Biomedical Nanomaterials, College of Materials Science and Engineering, Qingdao University of Science and Technology (QUST), Qingdao, 266042, P. R. China. qiaosl@qust.edu.cn.
  • Li ZY; Lab of Functional and Biomedical Nanomaterials, College of Materials Science and Engineering, Qingdao University of Science and Technology (QUST), Qingdao, 266042, P. R. China. qiaosl@qust.edu.cn.
  • Yu SS; Lab of Functional and Biomedical Nanomaterials, College of Materials Science and Engineering, Qingdao University of Science and Technology (QUST), Qingdao, 266042, P. R. China. qiaosl@qust.edu.cn.
  • Chen KZ; Lab of Functional and Biomedical Nanomaterials, College of Materials Science and Engineering, Qingdao University of Science and Technology (QUST), Qingdao, 266042, P. R. China. qiaosl@qust.edu.cn.
  • Qiao SL; Lab of Functional and Biomedical Nanomaterials, College of Materials Science and Engineering, Qingdao University of Science and Technology (QUST), Qingdao, 266042, P. R. China. qiaosl@qust.edu.cn.
J Mater Chem B ; 11(16): 3484-3510, 2023 04 26.
Article in English | MEDLINE | ID: covidwho-2288921
ABSTRACT
Messenger RNA (mRNA) has become a key focus in the development of therapeutic agents, showing significant potential in preventing and treating a wide range of diseases. The COVID-19 pandemic in 2020 has accelerated the development of mRNA nucleic therapeutics and attracted significant investment from global biopharmaceutical companies. These therapeutics deliver genetic information into cells without altering the host genome, making them a promising treatment option. However, their clinical applications have been limited by issues such as instability, inefficient in vivo delivery, and low translational efficiency. Recent advances in molecular design and nanotechnology have helped overcome these challenges, and several mRNA formulations have demonstrated promising results in both animal and human testing against infectious diseases and cancer. This review provides an overview of the latest research progress in structural optimization strategies and delivery systems, and discusses key considerations for their future clinical use.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pandemics / COVID-19 Type of study: Prognostic study Limits: Animals / Humans Language: English Journal: J Mater Chem B Year: 2023 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pandemics / COVID-19 Type of study: Prognostic study Limits: Animals / Humans Language: English Journal: J Mater Chem B Year: 2023 Document Type: Article